4-phenylbutyric acid has been researched along with Alzheimer Disease in 8 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In familial Parkinson's disease, accumulation of Parkin-associated endothelin receptor-like receptor (Pael-R), a substrate of ubiquitin ligase Parkin involved in ERAD, leads to ER stress and apoptosis." | 2.48 | [Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease]. ( Kaneko, M, 2012) |
| " However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day)." | 2.47 | Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. ( Cuadrado-Tejedor, M; Franco, R; García-Osta, A; Oyarzabal, J; Ricobaraza, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, C | 1 |
| Bonfili, L | 1 |
| Zheng, Y | 1 |
| Cecarini, V | 1 |
| Cuccioloni, M | 1 |
| Angeletti, M | 1 |
| Dematteis, G | 1 |
| Tapella, L | 1 |
| Genazzani, AA | 1 |
| Lim, D | 1 |
| Eleuteri, AM | 1 |
| Baumanns, S | 1 |
| Muehlemeyer, F | 1 |
| Miesbauer, LC | 1 |
| Baake, J | 1 |
| Roloff, EM | 1 |
| Beis, DM | 1 |
| Wenzel, U | 1 |
| Maulik, M | 1 |
| Vasan, L | 1 |
| Bose, A | 1 |
| Dutta Chowdhury, S | 1 |
| Sengupta, N | 1 |
| Das Sarma, J | 1 |
| Cuadrado-Tejedor, M | 4 |
| Ricobaraza, AL | 1 |
| Torrijo, R | 1 |
| Franco, R | 2 |
| Garcia-Osta, A | 4 |
| Ricobaraza, A | 3 |
| Pérez-Mediavilla, A | 1 |
| Frechilla, D | 1 |
| Del Río, J | 1 |
| Marco, S | 1 |
| Pérez-Otaño, I | 1 |
| Oyarzabal, J | 1 |
| Kaneko, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS[NCT04987671] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2021-08-05 | Active, not recruiting | ||
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 4-phenylbutyric acid and Alzheimer Disease
| Article | Year |
|---|---|
Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Humans; Phenylbutyrates | 2011 |
[Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Brain; Endoplasmic Reticulum | 2012 |
6 other studies available for 4-phenylbutyric acid and Alzheimer Disease
| Article | Year |
|---|---|
Immortalized Alzheimer's Disease Astrocytes: Characterization of Their Proteolytic Systems.
Topics: Alzheimer Disease; Animals; Astrocytes; Autophagy; Mice; Proteasome Endopeptidase Complex; Proteolys | 2023 |
4-Phenylbutyric acid attenuates amyloid-β proteotoxicity through activation of HSF-1 in an Alzheimer's disease model of the nematode Caenorhabditiselegans.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caenorhabditis elegans; Caenorhabditis elegans Pr | 2023 |
Amyloid-β regulates gap junction protein connexin 43 trafficking in cultured primary astrocytes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cells, Cultured; Connexin 43; Endocyt | 2020 |
Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Butyric Acid; C | 2013 |
Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Butyric Acid; C | 2013 |
Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Butyric Acid; C | 2013 |
Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Butyric Acid; C | 2013 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Dendritic S | 2012 |
Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Dendritic S | 2012 |
Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Dendritic S | 2012 |
Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Dendritic S | 2012 |